Testosterone therapy: many players and much controversy

The use of testosterone in men has become extremely controversial over the past year. Stakeholders in this topic include physicians who prescribe testosterone, patients—both those who feel that they benefited from treatment, and those who feel they have been harmed by treatment, the pharmaceutical companies, the federal government through the Food and Drug Administration (FDA), and litigation attorneys who have placed ads suggesting lawsuits for patients that have been on testosterone therapy and may have had cardiovascular events.

Like Comment

Authors

Mark Sigman, M.D.

Volume 103, Issue 5, Pages 1144-1145

Abstract

The use of testosterone in men has become extremely controversial over the past year. Stakeholders in this topic include physicians who prescribe testosterone, patients—both those who feel that they benefited from treatment, and those who feel they have been harmed by treatment, the pharmaceutical companies, the federal government through the Food and Drug Administration (FDA), and litigation attorneys who have placed ads suggesting lawsuits for patients that have been on testosterone therapy and may have had cardiovascular events.

Read the full text at: http://www.fertstert.org/article/S0015-0282(15)00204-6/fulltext

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.